Phaseline

Companies › Boryung Pharmaceutical

Boryung Pharmaceutical: clinical trials, targets and expected readouts

11 active drug programs in 73 registered trials: 22 Phase 3, 22 Phase 2, 19 Phase 1, 10 Phase 4; Cardiovascular, Oncology, Metabolic and endocrine, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dapagliflozin
Sodium/glucose cotransporter 2 inhibitor
SLC5A2Phase 4Type 2 Diabetes; Diabetes Mellitus; Diabete Mellitus–
BR1019A–Phase 3Essential HypertensionDec 2026
BR1019A-1–Phase 3Essential HypertensionDec 2026
BR1019B–Phase 3Essential HypertensionDec 2026
BR1019C–Phase 3Essential HypertensionDec 2026
Olanzapine
Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; D2-like dopamine receptor antagonist
HTR2A, HTR2C, DRD2, DRD3, DRD4Phase 2Schizophrenia; Schizophrenia and Related Disorders; Chemotherapy Induced Nausea and Vomiting; Oncology Patients Receiving Chemotherapy …May 2027
BR2021–Phase 1Metastatic Adenocarcinoma of the Pancreas–
BR2021-1–Phase 1Metastatic Adenocarcinoma of the Pancreas–
Metformin Hydrochloride
Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor
MT-ND6, NDUFA10, NDUFS8, MT-ND4L, NDUFA6Phase 1Diabetes Mellitus; Diabete Mellitus; Depression; Polycystic Ovary Syndrome …–
Olaparib (BR2022)
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2Phase 1Ovarian Cancer–
Pioglitazone
Peroxisome proliferator-activated receptor gamma agonist
PPARGPhase 1Diabetes Mellitus; Diabete Mellitus; Infertility Treatment; Type 2 Diabetes …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05919147PioglitazonePhase 2Lung CancerOncologyJun 2025
NCT04576104Metformin HydrochloridePhase 2Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial NeoplasiaOncologyAug 2025
NCT06867497BR2021Phase 1Metastatic Adenocarcinoma of the PancreasOncologyOct 2025
NCT06867497BR2021-1Phase 1Metastatic Adenocarcinoma of the PancreasOncologyOct 2025
NCT06850454OlanzapinePhase 3Chemotherapy Induced Nausea and VomitingOtherJan 2026
NCT07069335Olaparib (BR2022)Phase 1Ovarian CancerOncologyMay 2026
NCT07462065PioglitazonePhase 4Infertility TreatmentOtherJun 2026
NCT07083388DapagliflozinPhase 1Diabetes MellitusMetabolic and endocrineJul 2026
NCT07083388DapagliflozinPhase 1Diabetes MellitusMetabolic and endocrineJul 2026
NCT07083388PioglitazonePhase 1Diabetes MellitusMetabolic and endocrineJul 2026
NCT07083388Metformin HydrochloridePhase 1Diabetes MellitusMetabolic and endocrineJul 2026
NCT07083401DapagliflozinPhase 1Diabete MellitusMetabolic and endocrineJul 2026
NCT07083401DapagliflozinPhase 1Diabete MellitusMetabolic and endocrineJul 2026
NCT07083401PioglitazonePhase 1Diabete MellitusMetabolic and endocrineJul 2026
NCT07083401Metformin HydrochloridePhase 1Diabete MellitusMetabolic and endocrineJul 2026
NCT06972732DapagliflozinPhase 4Type 2 DiabetesMetabolic and endocrineOct 2026
NCT01905046Metformin HydrochloridePhase 3Breast Atypical Ductal HyperplasiaOncologyNov 2026
NCT06554613OlanzapinePhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT02336087Metformin HydrochloridePhase 1Pancreatic AdenocarcinomaOncologyDec 2026
NCT06220773BR1019APhase 3Essential HypertensionCardiovascularDec 2026
NCT06220773BR1019BPhase 3Essential HypertensionCardiovascularDec 2026
NCT06220773BR1019CPhase 3Essential HypertensionCardiovascularDec 2026
NCT06220773BR1019A-1Phase 3Essential HypertensionCardiovascularDec 2026
NCT05013255PioglitazonePhase 2Breast CancerOncologyDec 2026
NCT06707012Metformin HydrochloridePhase 4DepressionPsychiatryDec 2026
NCT05237960Metformin HydrochloridePhase 2ErythroplakiaOncologyDec 2026
NCT05023967Metformin HydrochloridePhase 2Anatomic Stage I Breast Cancer AJCC v8OncologyDec 2026
NCT02581137Metformin HydrochloridePhase 2ErythroplakiaOncologyDec 2026
NCT07633236OlanzapinePhase 3Oncology Patients Receiving ChemotherapyOncologyDec 2026
NCT05680805Metformin HydrochloridePhase 4Polycystic Ovary SyndromeMetabolic and endocrineDec 2026
NCT04939090OlanzapinePhase 3Advanced Malignant Solid NeoplasmOncologyDec 2026
NCT06989723PioglitazonePhase 4Type 2 DiabetesMetabolic and endocrineDec 2026
NCT04931017Metformin HydrochloridePhase 2Lung CarcinomaOncologyDec 2026
NCT03109288PioglitazonePhase 1Multiple SclerosisNeurologyJan 2027
NCT06611501Metformin HydrochloridePhase 2Pelvic PainGenitourinaryJan 2027
NCT06314906OlanzapinePhase 3ElectroacupunctureOncologyJan 2027
NCT03781115OlanzapinePhase 1SchizophreniaPsychiatryFeb 2027
NCT05893225Metformin HydrochloridePhase 2Multiple SclerosisNeurologyFeb 2027
NCT06338683OlanzapinePhase 3Advanced CancerOncologyMar 2027
NCT05305287PioglitazonePhase 4Non-Alcoholic Fatty Liver DiseaseMetabolic and endocrineMar 2027
NCT06821945OlanzapinePhase 2SchizophreniaPsychiatryMay 2027
NCT07056699PioglitazonePhase 3Type1diabetesMetabolic and endocrineJun 2027
NCT07053319PioglitazonePhase 1Type 2 DiabetesMetabolic and endocrineJun 2027
NCT07455955OlanzapinePhase 2Breast CancerOncologyJun 2027
NCT05705492OlanzapinePhase 2Advanced Malignant Solid NeoplasmOncologyJun 2027
NCT05445791Metformin HydrochloridePhase 3Non Small Cell Lung CancerOncologyJul 2027
NCT06446531PioglitazonePhase 1Pre-DiabetesCardiovascularJul 2027
NCT04758000Metformin HydrochloridePhase 2OsteosarcomaOncologyJul 2027
NCT04501406PioglitazonePhase 2Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineAug 2027
NCT07413809OlanzapinePhase 3Multiple MyelomaOncologySep 2027
NCT05895838OlanzapinePhase 3Out-Of-Hospital Cardiac ArrestCardiovascularSep 2027
NCT07387900Metformin HydrochloridePhase 2Oral LeukoplakiaOncologySep 2027
NCT04478838OlanzapinePhase 4Schizophrenia and Related DisordersPsychiatrySep 2027
NCT07699276OlanzapinePhase 2Cancer (Solid Tumors)OncologyOct 2027
NCT06588413OlanzapinePhase 3Multiple MyelomaOncologyOct 2027
NCT06200181OlanzapinePhase 3Misuse, OpioidPsychiatryNov 2027
NCT05230758Metformin HydrochloridePhase 3Medulloblastoma, ChildhoodOncologyNov 2027
NCT06657209PioglitazonePhase 4Diabetes Mellitus, Type 2Metabolic and endocrineDec 2027
NCT02889003PioglitazonePhase 2Chronic Myeloid Leukemia (CML)OncologyDec 2027
NCT02767063PioglitazonePhase 1Leukemia, Myeloid, Chronic-PhaseOncologyDec 2027

The 60 nearest readouts of 73 trials; the rest in the app.

Targets

SLC5A2 (1) HTR2A (1) HTR2C (1) DRD2 (1) DRD3 (1) DRD4 (1) PPARG (1) MT-ND6 (1) NDUFA10 (1) NDUFS8 (1) MT-ND4L (1) NDUFA6 (1)

Companies with the same targets

Serina Therapeutics MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals Vanda Pharmaceuticals Intra-Cellular Therapies Sichuan Kelun Pharmaceutical Otsuka Tonix Pharmaceuticals LB Pharmaceuticals Gedeon Richter Anxo Pharmaceutical

Companies built like this

Tasly Pharmaceuticals JW Pharmaceutical Yuhan Sinotau Pharmaceutical Group Shenzhen Salubris Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.